Cargando…
Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany
BACKGROUND: Steady evolution of therapies has improved prognosis of patients with multiple myeloma (MM) over the past two decades. Yet, knowledge about survival trends and causes of death in MM might play a crucial role in long-term management of this patient collective. Here, we investigate time tr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080943/ https://www.ncbi.nlm.nih.gov/pubmed/37024813 http://dx.doi.org/10.1186/s12885-023-10787-5 |
_version_ | 1785021019264647168 |
---|---|
author | Eisfeld, Christine Kajüter, Hiltraud Möller, Lennart Wellmann, Ina Shumilov, Evgenii Stang, Andreas |
author_facet | Eisfeld, Christine Kajüter, Hiltraud Möller, Lennart Wellmann, Ina Shumilov, Evgenii Stang, Andreas |
author_sort | Eisfeld, Christine |
collection | PubMed |
description | BACKGROUND: Steady evolution of therapies has improved prognosis of patients with multiple myeloma (MM) over the past two decades. Yet, knowledge about survival trends and causes of death in MM might play a crucial role in long-term management of this patient collective. Here, we investigate time trends in myeloma-specific survival at the population level over two decades and analyse causes of death in times of prolonged survival. METHODS: Age-standardised and age group-specific relative survival (RS) of MM patients aged < 80 years at diagnosis was estimated for consecutive time periods from 2000–2019 using data from the Cancer Registry of North Rhine-Westphalia in Germany. Conditional RS was estimated for patients who already survived one to five years post diagnosis. Causes of death in MM patients were analysed and compared to the general population using standardised mortality ratios (SMR). RESULTS: Three thousand three hundred thirty-six MM cases were included in the time trend analysis. Over two decades, age-standardised 5-year RS increased from 37 to 62%. Age-specific survival improved from 41% in period 2000–2004 to 69% in period 2015–2019 in the age group 15–69 years, and from 23 to 47% in the age group 70–79 years. Conditional 5-year RS of patients who survived five years after diagnosis slightly improved as compared to unconditional 5-year RS at diagnosis. MM patients are two times more likely to die from non-myeloma malignancies (SMR = 1.97, 95% CI 1.81–2.15) and from cardiovascular diseases (SMR = 2.01, 95% CI 1.86–2.18) than the general population. CONCLUSIONS: Prognosis of patients with MM has markedly improved since the year 2000 due to therapeutic advances. Nevertheless, late mortality remains a major concern. As survival improves, second primary malignancies and cardiovascular events deserve increased attention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10787-5. |
format | Online Article Text |
id | pubmed-10080943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100809432023-04-08 Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany Eisfeld, Christine Kajüter, Hiltraud Möller, Lennart Wellmann, Ina Shumilov, Evgenii Stang, Andreas BMC Cancer Research BACKGROUND: Steady evolution of therapies has improved prognosis of patients with multiple myeloma (MM) over the past two decades. Yet, knowledge about survival trends and causes of death in MM might play a crucial role in long-term management of this patient collective. Here, we investigate time trends in myeloma-specific survival at the population level over two decades and analyse causes of death in times of prolonged survival. METHODS: Age-standardised and age group-specific relative survival (RS) of MM patients aged < 80 years at diagnosis was estimated for consecutive time periods from 2000–2019 using data from the Cancer Registry of North Rhine-Westphalia in Germany. Conditional RS was estimated for patients who already survived one to five years post diagnosis. Causes of death in MM patients were analysed and compared to the general population using standardised mortality ratios (SMR). RESULTS: Three thousand three hundred thirty-six MM cases were included in the time trend analysis. Over two decades, age-standardised 5-year RS increased from 37 to 62%. Age-specific survival improved from 41% in period 2000–2004 to 69% in period 2015–2019 in the age group 15–69 years, and from 23 to 47% in the age group 70–79 years. Conditional 5-year RS of patients who survived five years after diagnosis slightly improved as compared to unconditional 5-year RS at diagnosis. MM patients are two times more likely to die from non-myeloma malignancies (SMR = 1.97, 95% CI 1.81–2.15) and from cardiovascular diseases (SMR = 2.01, 95% CI 1.86–2.18) than the general population. CONCLUSIONS: Prognosis of patients with MM has markedly improved since the year 2000 due to therapeutic advances. Nevertheless, late mortality remains a major concern. As survival improves, second primary malignancies and cardiovascular events deserve increased attention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10787-5. BioMed Central 2023-04-06 /pmc/articles/PMC10080943/ /pubmed/37024813 http://dx.doi.org/10.1186/s12885-023-10787-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Eisfeld, Christine Kajüter, Hiltraud Möller, Lennart Wellmann, Ina Shumilov, Evgenii Stang, Andreas Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany |
title | Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany |
title_full | Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany |
title_fullStr | Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany |
title_full_unstemmed | Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany |
title_short | Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany |
title_sort | time trends in survival and causes of death in multiple myeloma: a population-based study from germany |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080943/ https://www.ncbi.nlm.nih.gov/pubmed/37024813 http://dx.doi.org/10.1186/s12885-023-10787-5 |
work_keys_str_mv | AT eisfeldchristine timetrendsinsurvivalandcausesofdeathinmultiplemyelomaapopulationbasedstudyfromgermany AT kajuterhiltraud timetrendsinsurvivalandcausesofdeathinmultiplemyelomaapopulationbasedstudyfromgermany AT mollerlennart timetrendsinsurvivalandcausesofdeathinmultiplemyelomaapopulationbasedstudyfromgermany AT wellmannina timetrendsinsurvivalandcausesofdeathinmultiplemyelomaapopulationbasedstudyfromgermany AT shumilovevgenii timetrendsinsurvivalandcausesofdeathinmultiplemyelomaapopulationbasedstudyfromgermany AT stangandreas timetrendsinsurvivalandcausesofdeathinmultiplemyelomaapopulationbasedstudyfromgermany |